"id","uuid:ID","rationale","instanceType","versionIdentifier"
"StudyVersion_1","112e3f0a-a514-4a4f-9106-c69ad63094ea","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","2"
